NIH Launches Second Phase of Patient Reported Outcomes Initiative
News Oct 19, 2009
The National Institutes of Health announced that it is awarding 15 new grants to further develop and test the Patient Reported Outcomes Measurement Information System (PROMIS).
Managed by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), PROMIS aims to revolutionize the way patient reported outcome tools are selected and employed in clinical research and practice.
PROMIS utilizes advances in computer technology and modern measurement theory to assess outcomes such as pain, fatigue, and other aspects of quality of life in a standardized manner. An important goal of the initiative is to develop valid and reliable clinical instruments that will allow the measurement of patient-reported symptoms.
"Due to the success of PROMIS and growing interest of various research and health care communities, the NIH Roadmap mechanism has allowed an additional four years of funding for this initiative," said Raynard S. Kington, M.D., Ph.D., deputy director, NIH. "The second phase of PROMIS will continue to advance the field of patient self-reporting by conducting large-scale validation studies in a variety of clinical populations."
"These outcomes have a major impact on quality of life across a variety of chronic diseases and are often the best way to judge the value of treatments," said NIAMS director Stephen I. Katz, M.D., Ph.D. "An important priority during the second funding phase of this initiative will be to strengthen assessment of patient-reported outcomes in all relevant population groups, including minorities, women, underserved individuals, and children."
The PROMIS network will support a comprehensive, integrated approach to data collection, storage, and management and will consist of three administrative centers and 12 research sites. The initiative is designed to be a vital resource for the clinical research community.
According to Josephine P. Briggs, M.D., director of the National Center for Complementary and Alternative Medicine (NCCAM), "PROMIS holds potential to provide very valuable standardized measurement tools that will allow greater comparability of studies, and substantially reduce the burden on patients participating in research studies."
Existing 20-year-old Multiple Sclerosis Drug Effective Against Multi-resistant BacteriaNews
A widely-used and twenty-year-old medicine used to treat multiple sclerosis can also beat a type of multi-resistant bacteria for which there are currently only a few effective drugs.READ MORE
Revolutionary Imaging Technique Uses CRISPR to Map DNA MutationsNews
The new high-speed AFM method can map DNA to a resolution of tens of base pairs while creating images up to a million base pairs in size. And it does it using a fraction of the amount of specimen required for DNA sequencing.READ MORE
AIDS Vaccine Design: New Data Offers Important InsightNews
New data published in Immunity further illuminate how some human beings generate powerful, HIV-blocking antibodies. The results offer important insight into a potential AIDS vaccine design.READ MORE